title: Autologous bone marrow mixed with HLA-haploidentical allogeneic marrow transplantation for treatment of patients with malignant blood diseases.
abstract: We have previously demonstrated that syngeneic marrow mixed with H-2 haploidentical marrow transplantation could provide not only protection against graft-versus-host disease (GVHD) but also anti-leukemic (GVL) effects in mice. In the present studies, we report clinical observations using autologous marrow mixed with HLA-haploidentical allogeneic marrow transplantation for treatment of patients with malignant blood diseases. Sixteen cases, including 12 with acute leukemia and four with advanced malignant lymphoma, were treated by autologous marrow, which was purged in vitro by hyperthemia (42.5 degrees C for 70 min) following incubation for 5 days with interleukin 2 (IL-2) in liquid culture and mixed with HLA haploidentical marrow cells from their sibling or parent. Acute GVHD was not observed in any patient after transplantation. Hematological rescue in the clinical setting was demonstrated in all cases but one who died early from hepatic veno-occlusive disease (VOD). Five cases who were transplanted at the time of CR2 or CR3 and in advanced phase of lymphoma, relapsed 4 to 7 months after transplantation. The relapse rate was 31.3%. None of eight patients who received allogeneic BMT within 2 h after ABMT relapsed with median follow-up of 12 months and two of them died from procedure-related complications. Seven cases are still alive and disease-free with a median follow-up of 12 months. Mixed chimerism was found in 3/6 cases, who had different sex donors, by analysis of sex chromosomes. These results show that mixed transplantation is a safe, effective and new approach to treating patients with malignant tumors. In order to detect the effects of GVL, studies are now in progress in our clinic.
authors.affiliation: Department of Hematology, Lanzhou Institute of Hematology, Lanzhou General Hospital, Gansu Province, China.
authors.forename: W M
authors.initials: WM
authors.lastname: Da
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: J T
authors.initials: JT
authors.lastname: Zhong
authors.forename: H
authors.initials: H
authors.lastname: Bai
authors.forename: M J
authors.initials: MJ
authors.lastname: Ji
authors.forename: C B
authors.initials: CB
authors.lastname: Wang
authors.forename: J Z
authors.initials: JZ
authors.lastname: Lu
authors.forename: J M
authors.initials: JM
authors.lastname: Chen
authors.forename: Y L
authors.initials: YL
authors.lastname: Wang
authors.forename: X X
authors.initials: XX
authors.lastname: Wu
authors.forename: S F
authors.initials: SF
authors.lastname: Xu
authors.forename: Q
authors.initials: Q
authors.lastname: Zhang
authors.forename: Y M
authors.initials: YM
authors.lastname: Wei
mesh_terms: D000328:Adult; D000818:Animals; D016026:Bone Marrow Transplantation; D005260:Female; D006680:HLA Antigens; D019337:Hematologic Neoplasms / Q000628:therapy*; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D051379:Mice; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens